PRESS RELEASE published on 08/04/2025 at 07:00, 4 months ago Inside Information / Other news releases Innate Pharma discloses total shares outstanding and voting rights as of August 1, 2025. The company is a global biotech developing immunotherapies for cancer patients Voting Rights Biotechnology Immunotherapy Innate Pharma Shares Outstanding
BRIEF published on 07/04/2025 at 07:05, 5 months ago Innate Pharma Announces Share and Voting Rights Update Voting Rights Shares Euronext Nasdaq Innate Pharma
PRESS RELEASE published on 07/04/2025 at 07:00, 5 months ago Inside Information / Other news releases Innate Pharma discloses number of shares and voting rights as of July 3, 2025, in accordance with French regulations. Total shares: 92,183,523. Total voting rights: 92,962,943 (theoretical) and 92,944,368 (exercisable) Voting Rights Shares French Regulations Financial Disclosure Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 5 months 17 days ago Innate Pharma to Participate in Key Investor Conferences Biotechnology Investor Conferences Healthcare Immunotherapy Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 5 months 17 days ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 5 months 21 days ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
PRESS RELEASE published on 06/13/2025 at 07:00, 5 months 21 days ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 6 months 22 days ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 6 months 22 days ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 7 months 2 days ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
Published on 12/05/2025 at 02:35, 2 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 51 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 31 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 56 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 6 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 11 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 37 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 21 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
